Fastest
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →https://www.patsnap.com/resources/blog/rd-blog/microcarrier-cell-culture-harvest-timing-patent-landscape/ · Patsnap · data cut-off 2026-07-31 · downloaded from the live page
Patent Landscape BriefMicrocarrier Cell Culture Harvest Timing Patents: Who Holds the Claims
- 58 published records sit across a narrow IPC footprint dominated by C12N (79.3%) and C12M (72.4%), meaning most claims are written as biology or apparatus, not as software or imaging.
- Filings peaked in 2022 at 14 then eased to 2 by 2024 (down 50% from 2021's 4) — though 2025-2026 counts are still filling in given an 18-month publication lag.
- One leader holds 23 records against a fifth-place assignee at 3 and a tenth-place assignee at 1, leaving a long tail of single- and low-filing entrants below the top of the ranking.
58
Published Records
-50%
Filing Growth 2021→2024
US
Leading Jurisdiction
19
Active Filers Ranked
Filing growth compares 2021 (4 records) with 2024 (2) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field.
Published byPatsnap Research··7 min readSourced from Patsnap Eureka
Overview
What this landscape covers
This brief tracks 58 published patent records at the intersection of microcarrier and adherent cell culture practice with harvest-timing signals — viability decline, product titer, impurity release, apoptosis markers, harvest window and quality attribute language — filed under the core bioreactor and cell-culture IPC groups (C12N5/00, C12M3/00, C12M1/12). It is a narrow, applied slice of cell-therapy manufacturing IP rather than a broad culture-media or genetic-engineering search.
Coverage runs from 2015-01-01 to the 2026-07-31 data cut-off. Because publication typically lags filing by roughly 18 months, the last one to two years of the trend line will keep rising as more filings clear examination and publish; treat 2025 and 2026 counts as provisional, not as evidence of a slowdown.
Filing activity and technology composition, 2017-2026
Source: Patsnap Eureka. Assignee ranking and totals. Derived from a Patsnap search on Microcarrier Cell Culture Harvest Timing covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
10,000 free credits to start
The data
Filing trend and technology mix
Two views of the same 58-record set: how filing activity has moved year over year, and which IPC subclasses those records actually sit in.
Filing activity, 2017-2026
Filings rose from 3 in 2017 to a peak of 14 in 2022, then declined to 2 by 2024 — a 50% drop from the 2021 level of 4 over that three-year span. 2025 and 2026 figures are still incomplete due to publication lag and should not be read as a trend reversal or a continued fall.
Technology composition by IPC subclass
C12N (microorganisms and genetic engineering) and C12M (bioreactors and enzyme apparatus) anchor the field at 79.3% and 72.4% of the 58 records respectively. Analytical and imaging-adjacent classes — B01L, G01N and G06T — each sit near a third of records, while C07K (peptides and proteins) and C12P (fermentation) appear in a smaller minority. Records can carry more than one class, so these shares sum past 100%.
Shares are the percentage of the 58 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Source: Patsnap Eureka. Filing trend and technology composition. Derived from a Patsnap search on Microcarrier Cell Culture Harvest Timing covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.
Go deeper on Microcarrier Cell Culture Harvest Timing with Eureka
This page is one run against one query. Ask Eureka your own question about microcarrier cell culture harvest timing and every answer comes back with the patent numbers behind it.
Try EurekaKey patents
Most-cited records in this set
Representative filing
Platforms and systems for automated cell culture
CELLINO BIOTECH, INC.
Disclosed herein are platforms, systems, and methods including a cell culture system that includes a cell culture container comprising a cell culture, the cell culture receiving input cells, a cell imaging subsystem configured to acquire images of the cell culture, a computing subsystem configured to perform a cell culture process on the cell culture according to the images acquired by the cell imaging subsystem, and a cell editing subsystem configured to edit the cell culture to produce output cell products according to the cell culture process.Filed by Cellino Biotech, published 2022-09-08. The claim architecture ties imaging-driven process control directly to the culture and editing hardware, which is one reason it anchors the automated end of this landscape.
Highest-citation records
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US5661023A | Production and purification of retroviral particles using tentacle anion exchange | 36 |
| 2 | US20230065504A1 | Platforms and systems for automated cell culture | 30 |
| 3 | WO2022076519A1 | Cell culture harvest and reseed methods and systems using dissolvable substrates | 29 |
| 4 | US20190048305A1 | Perfusion bioreactor and method for using same to perform a continuous cell culture | 28 |
| 5 | US20180298343A1 | Compositions and methods for a three dimensional ex-vivo glomerular cell co-culture biological engineering mo… | 24 |
| 6 | WO1995025789A1 | Highly efficient production and isolation of viral particles | 23 |
| 7 | US20220282201A1 | Platforms and systems for automated cell culture | 16 |
| 8 | US20160002594A1 | Microcarrier perfusion culturing methods and uses thereof | 16 |
| 9 | US20220282203A1 | Platforms and systems for automated cell culture | 15 |
| 10 | US6080571A | Highly efficient production and isolation of viral particles utilizing tentacle anion exchange | 14 |
Citation counts inside this corpus skew toward older filings, which have had more time to accumulate citations — read them as a signal of influence on the field, not as a ranking of current commercial relevance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Source: Patsnap Eureka. Citation counts and representative records. Derived from a Patsnap search on Microcarrier Cell Culture Harvest Timing covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Run it yourself
Put your own technology through the same analysis
Where to run it
For builders
MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →Insights
What the numbers mean for filing strategy
Three observations that follow directly from the ranking, the trend line and the IPC mix above.
Concentration at the top
23 vs 3
leader vs fifth place
One assignee outpaces the rest of the ranked field
The leading assignee in the 19-company ranking holds 23 records, while fifth place holds 3 and tenth place holds just 1. That gap suggests one organisation built an early, sustained filing program around harvest-timing signals while most other entrants filed opportunistically or once.
Based on the assignee ranking of 19 companies
Peak-then-cool filing pattern
14 in 2022
peak year
Activity crested in 2022 and has since eased
Filings climbed from 3 in 2017 to a peak of 14 in 2022, then fell to 2 by 2024 — a 50% decline from the 2021 level of 4. Because 2025-2026 records are still publishing, this reads as a genuine post-peak cooling through 2024 rather than a market that has gone quiet.
2021 to 2024 change; later years still filling in
Apparatus and biology dominate
79.3% / 72.4%
C12N / C12M share of 58 records
Claims sit in bioreactor and cell-biology language, not software
C12N and C12M cover the large majority of records, while imaging- and analytics-adjacent classes (B01L, G01N, G06T) each sit near a third. Software-flavoured classification such as G06K appears in only 6.9% of records, which is a narrower footprint than the imaging hardware in the featured filing might suggest.
Shares of the 58 records in scope; a record can carry multiple classes
Eureka AI Agent
Looking for what nobody has claimed yet?
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to microcarrier cell culture harvest timing, with the prior art for and against each one.
Source: Patsnap Eureka. Co-assignee relationships and derived observations. Derived from a Patsnap search on Microcarrier Cell Culture Harvest Timing covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Players
Who is filing, and where the activity is thin
The ranked field spans 19 companies, from a clear leader down to entrants with a single record. Recent-year momentum across the top names has flattened, which is consistent with the post-2022 filing cool-down rather than any one company pulling ahead.
Leader by volume
23 records
top of the ranking
A single assignee anchors the field
The top-ranked assignee's 23 records place it well ahead of the rest of the 19-company ranking, indicating a deliberate, multi-year filing program rather than a handful of related applications.
Assignee ranking, 19 companies
Mid-table entrants
3 records
fifth place
A cluster of moderate filers below the leader
Fifth place in the ranking holds 3 records, marking the point where filing volume drops off sharply from the leader and settles into a more even mid-table.
Assignee ranking, 19 companies
Long tail
1 record
tenth place
Most of the ranked field filed once or twice
By tenth place the ranking is down to a single record, and the pattern continues below that point — a long tail of organisations that filed on this specific harvest-timing intersection only once.
Assignee ranking, 19 companies
Recent-year momentum
0 latest year
across top assignees tracked
Momentum has flattened across the leading names
Every top assignee tracked for recent-year momentum, including the overall leader, shows 0 records in the latest year — consistent with the broader post-2022 filing cool-down and the publication lag still working through 2025-2026 data.
Recent-year momentum by assignee
Recent-year filing momentum by assignee
| Assignee | Recent year | YoY |
|---|---|---|
| CELLINO BIOTECH INC | 0 | — |
| Genzyme Corp | 0 | — |
| The Immune Response Corp | 0 | — |
| Global Life Sciences Solutions USA LLC | 0 | — |
| Corning Inc | 0 | — |
| XCELLEREX LLC | 0 | — |
| UNICORN BIOTECHNOLOGIES LTD | 0 | — |
| Rhone Poulenc Rorer Pharmaceuticals Inc | 0 | — |
Source: Patsnap Eureka. Assignee-level momentum. Derived from a Patsnap search on Microcarrier Cell Culture Harvest Timing covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
What's next
Where to take this next
The dataset points to a concentrated leader, a cooling filing curve, and analytical sub-areas that remain thinly claimed.
Map claims against your own process steps
Cross-check the featured and most-cited records against your specific harvest-trigger logic — viability threshold, titer assay, or imaging cue — before assuming a given step is open.
Explore in Eureka →Watch the mid-table for acquisition signals
Entrants with 3 or fewer records are the ones most likely to license out or be acquired rather than build out a full portfolio; track their filing status over the next publication cycle.
Track assignees in Eureka →Revisit the trend once 2025-2026 data settles
Because publication lags filing by roughly 18 months, the true 2025 and 2026 filing counts will not be visible for some time; re-pull this view once those years complete.
Set an alert in Eureka →Source: Patsnap Eureka. Forward-looking reading of the same dataset. Derived from a Patsnap search on Microcarrier Cell Culture Harvest Timing covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
FAQ
Common questions on this landscape
The assignee ranking for this dataset covers 19 companies, and the leader holds 23 of the 58 published records in scope — well ahead of fifth place, which holds 3. That gap points to a single organisation running a sustained, multi-year filing program around harvest-timing signals such as viability decline and product titer, while most other ranked entrants filed only a handful of times. It does not mean that one company controls the whole field, since the ranking only reflects records matching this specific search and IPC scope.
Filings rose from 3 in 2017 to a peak of 14 in 2022, then fell to 2 by 2024 — a 50% decline from the 2021 level of 4. Because patent publication typically lags actual filing by around 18 months, the 2025 and 2026 counts in this dataset are still incomplete and should not yet be read as confirmation of a continued decline. The honest read through the last complete year, 2024, is a cool-down from a 2022 peak, not a dead field.
C12N (microorganisms and genetic engineering) and C12M (bioreactors and enzyme apparatus) are the two dominant subclasses, covering 79.3% and 72.4% of the 58 records in scope respectively. Analytical and imaging-related classes — B01L, G01N and G06T — each sit near a third of records, while peptide and fermentation classes (C07K, C12P) appear in a smaller minority. Since a single record can carry several IPC classes, these percentages add up to more than 100% and should not be treated as mutually exclusive shares of one whole.
US20220282203A1, filed by Cellino Biotech and published 2022-09-08, discloses a cell culture platform that ties an imaging subsystem, a computing subsystem, and a cell-editing subsystem together so that culture process decisions are driven directly by acquired images. Anyone building an automated harvest-timing system that uses image data to trigger a process change on the same culture should review this filing's specific claim language before assuming a clear path. It is one of the most-cited records in this dataset, which signals it has already shaped how competitors and examiners frame automated culture-imaging claims.
The IPC composition shows software- and recognition-flavoured classification, such as G06K, appearing in only 6.9% of the 58 records, well below the apparatus- and biology-heavy C12N and C12M classes. That gap suggests claim language built specifically around real-time sensing algorithms, dissolvable-substrate reseed methods, or continuous-perfusion harvest-window control is comparatively thin. A first claim in one of these branches would likely combine a specific sensing or substrate mechanism with an explicit harvest-trigger step, rather than relying on the broad platform-level claims that dominate the most-cited records.
Answers are grounded in the same dataset. Derived from a Patsnap search on Microcarrier Cell Culture Harvest Timing covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Research Microcarrier Cell Culture Harvest Timing in depth with Eureka
Go past this page: query the whole microcarrier cell culture harvest timing corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company's registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.